Dharmacon to support Genentech drug discovery
Genentech has selected Dharmacon's advanced RNAi technology for use in its drug discovery and development research.
Genentech has selected Dharmacon's advanced RNAi technology for use in its drug discovery and development research.
Under an agreement between the two companies, Dharmacon will supply Genentech with a range of siRNA reagents including Dharmacon's Human Drugable Genome library, which focuses on those genes that are considered potential targets for therapeutics. Further terms were not disclosed.
'We believe this agreement is further indication that Dharmacon's SMARTselection and SMARTpool technologies are a preferred gene-silencing platform for drug discovery research among leading pharma-ceutical and biotechnology companies,' said Leland Foster, president and ceo of the biosciences group of Fisher Scientific International.
Dharmacon provides RNA oligonucleotides, small interfering RNA (siRNA) and related RNA-interference (RNAi) products and technologies and has used its core expertise in chemistry, biology, bioinformatics and production to pioneer a custom siRNA design service that employs its proprietary technologies for maximizing the efficiency of gene silencing, a powerful and increasingly widely-used new technology.